Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Charli xcx teases new film ‘The Moment’: What to know about the A24 movie - 25 Morning Schedules That Stimulate Your Day
- 3NASA’s Pandora telescope will study stars in detail to learn about the exoplanets orbiting them
- 46 Famous Urban communities for Shopping on the planet
- 5Flourishing in a Remote Workplace: Individual Techniques
- Soldiers seize power in Guinea-Bissau and detain the president
- The wolf supermoon will kick off 2026 with a celestial bang. Here's when and how to see it.
- 2 ways you can conserve the water used to make your food
- How to watch the 2025 Macy's Thanksgiving Day Parade for free
- Nikki Glaser has been testing out Golden Globes jokes. There's one nobody wants to hear
- The most effective method to Look at Medical caretaker Compensations Across Various Clinics
- How will the universe end?
- Curl Up With Some Hot Chocolate And Watch Mighty Car Mods Explore Japan In A Honda City Turbo II
- Find Your Ideal Tea: Six Particular Assortments
